Glucagon-Like Peptide-1 (GLP-1) Agonist.
- Author:
Young Sil EOM
1
;
Byung Joon KIM
Author Information
1. Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea. kbjoon4u@gilhospital.com
- Publication Type:Review
- Keywords:
Glucagon-like peptide 1 analogue;
Incretin;
Type 2 diabetes
- MeSH:
Diabetes Mellitus, Type 2;
Glucagon-Like Peptide 1*;
Glucose;
Humans;
Incretins;
Insulin;
Prevalence
- From:Korean Journal of Medicine
2014;87(1):9-13
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications. Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes, but the effects of those treatments are suboptimal. The two incretin hormones GLP-1 and GIP are released from L- and K-cells, respectively, in response to nutrient intake. GLP-1 stimulates glucose-dependent insulin release. Recently, incretin hormone-based therapies, including GLP-1 agonists and DPP-4 inhibitors, have been used as new treatment options to control glucose levels in patients with type 2 diabetes mellitus. The purpose of this article is to review the efficacy and safety of GLP-1 agonists in the treatment of type 2 diabetes.
